Table 2. Overview of the obtained results for the 15 oxy-PAHs and their effects on the five assayed endpoints.

	AHR activator (EROD) a	AHR activator (CYP1 mRNA) b , c	CYP1A1 inhibitor (IC50) d	TCDD interaction (EROD) e	TCDD interaction (CYP1 mRNA) e , c
1-INO	=	ND	=	=	ND
1H-PHO	=	↑	=	↓	↓
9-FLO	=	=	↓	=	↓
1,2-ACNQ	=	ND	=	=	ND
4H-CPO	↑	↓	↓↓	↓	↓
9,10-PQ	=	↑	↓↓	=	=
9,10-AQ	=	↓	=	↓↓	↓
2-MAQ	↑	↑	↓	↓	↓
7H-BAO	=	↑	↓↓	↓	↓
BFLO	↑↑	↑↑	↓↓	↓↓	↓↓
2,3-DMAQ	↑	↑	↓	↓↓	↓↓
6H-BPO	↑	↓	↓↓	↓↓	↓↓
1,4-CHRQ	=	↑↑	↓	↓	=
5,12-NQ	↑↑	↑↑	↓	↓↓	=
7,12-BAQ	↑↑	↑↑	↓↓	↓↓	=

^a↑↑Strong inducer (≥BP and p < 0.05), ↑inducer (p < 0.05), = no significant effect.

^b↑↑Strong inducer (≥20-fold and p < 0.05), ↑inducer (<20-fold and p < 0.05), = no significant effect, ↓inhibitor (p < 0.05), ND not determined.

^cSince the effects on the CYP1A1 and 1B1 mRNA levels were very similar they are described together as CYP1 mRNA.

^d↓↓Strong inhibitor (IC₅₀ < 1 μM), ↓inhibitor (1 μM < IC₅₀ < 10 μM), = no effect (IC₅₀ >10 μM).

^e↓↓Strong inhibitor (p < 0.05 at ≤1 μM oxy-PAH), ↓inhibitor (p < 0.05 at 10 μM oxy-PAH), = no significant effect, ND not determined.